Author's Proof

Before checking your proof, please read the instructions below

- Carefully read the entire proof and mark all corrections in the appropriate place, using the Adobe Reader commenting tools (Adobe Help).
- Provide your corrections in a single PDF file or post your comments in the Production Forum making sure to reference the relevant query/line number. Upload or post all your corrections directly in the Production Forum to avoid any comments being missed.
- We do not accept corrections in the form of edited manuscripts nor via email.
- Before you submit your corrections, please make sure that you have checked your proof carefully as once you approve it, you won’t be able to make any further corrections.
- To ensure the timely publication of your article, please submit the corrections within 48 hours. After submitting, do not email or query asking for confirmation of receipt.

Do you need help? Visit our Production Help Center for more information. If you can’t find an answer to your question, contact your Production team directly by posting in the Production Forum.

Quick Check-List

- **Author names** - Complete, accurate and consistent with your previous publications
- **Affiliations** - Complete and accurate. Follow this style when applicable: Department, Institute, University, City, Country
- **Tables** - Make sure our formatting style did not change the meaning/alignment of your Tables.
- **Figures** - Make sure we are using the latest versions.
- **Funding and Acknowledgments** - List all relevant funders and acknowledgments.
- **Conflict of Interest** - Ensure any relevant conflicts are declared.
- **Supplementary files** - Ensure the latest files are published and that no line numbers and tracked changes are visible. Also, the supplementary files should be cited in the article body text.
- **Queries** - Reply to all typesetters queries below
- **Content** - Read all content carefully and ensure any necessary corrections are made.

Author Queries Form

| Q1       | Confirm whether the insertion of the article title is correct. |
|----------|---------------------------------------------------------------|
| Q2       | The citation and surnames of all of the authors have been highlighted. Check that they are correct and consistent with the authors’ previous publications, and correct if need be. Please note that this may affect the indexing of your article in repositories such as PubMed. |
| Q3       | Confirm that the email address in your correspondence section is accurate. |
| Q4       | Please confirm if this should be “These authors have contributed equally to this work”. |
| Q5       | Please ask the following authors to register with Frontiers (at https://www.frontiersin.org/Registration/Register.aspx) if they would like their names on the article abstract page and PDF to be linked to a Frontiers profile. Please ensure to provide us with the profile link(s) when submitting the proof corrections. Non-registered authors will have the default profile image displayed “Marta Cozzi” “Paola Rusmini” |
| Q6 | Confirm that all author affiliations are correctly listed. Note that affiliations are listed sequentially as per journal style and requests for non-sequential listing will not be applied. Note that affiliations should reflect those at the time during which the work was undertaken. |
| Q7 | Confirm that the keywords are correct and keep them to a maximum of eight and a minimum of five. (Note: a keyword can be comprised of one or more words.) Note that we have used the keywords provided at Submission. If this is not the latest version, please let us know. |
| Q8 | Check if the section headers (i.e., section leveling) were correctly captured. |
| Q9 | Confirm that the short running title is correct, making sure to keep it to a maximum of five words. |
| Q10 | If you decide to use previously published, copyrighted figures in your article, please keep in mind that it is your responsibility, as the author, to obtain the appropriate permissions and licenses and to follow any citation instructions requested by third-party rights holders. If obtaining the reproduction rights involves the payment of a fee, these charges are to be paid by the authors. |
| Q11 | Ensure that all the figures, tables and captions are correct, and that all figures are of the highest quality/resolution. Please note that Figures and Tables must be cited sequentially. |
| Q12 | Verify that all the equations and special characters are displayed correctly. |
| Q13 | Figures 1G, H have not been mentioned in the article. Please add a citation within the text, noting that Figures and Tables must appear in sequence. |
| Q14 | Provide the meaning of the symbol “*, ** and ***” provided in Figure 2. |
| Q15 | The image used in Figure 4 does not have any *** symbol; however, **** is present in the caption. Could you clarify this? Provide revised files if necessary. |
| Q16 | Figure 5 has not been mentioned in the article. Please add a citation within the text, noting that Figures must appear in sequence. |
| Q17 | Confirm that the Data Availability statement is accurate. Note that we have used the statement provided at Submission. If this is not the latest version, please let us know. |
| Q18 | Ensure to add all grant numbers and funding information, as after publication this will no longer be possible. All funders should be credited and all grant numbers should be correctly included in this section. |
| Q19 | Ensure that any supplementary material is correctly published at this link: https://www.frontiersin.org/articles/10.3389/fonc.2021.652085/full#supplementary-material
If the link does not work, you can check the file(s) directly in the production forum; the published supplementary files appear in green.
Provide new files if you have any corrections and make sure all Supplementary files are cited.
Please also provide captions for these files, if relevant.
Note that ALL supplementary files will be deposited to FigShare and receive a DOI.
Notify us of any previously deposited material.
If the Supplementary Material files contain identifiable images, please keep in mind that it is your responsibility, as the author, to ensure you have permission to use the images in the article. Please check this [link](#) for author's responsibility for publication of identifiable images. |
| Q20 | Confirm that the details in the “Author Contributions” section are correct and note that we have added the sentence “All authors contributed to the article and approved the submitted version.” |
| Q21 | Please provide page range of Ref. 6. |
| Q22 | Please provide volume number and page range of Refs. 11, 12, 16, 27 and 33. |
| Q23 | Confirm if the text included in the Conflict of Interest statement is correct. |
Retinoic Acid Downregulates HSPB8 Gene Expression in Human Breast Cancer Cells MCF-7

Margherita Piccolella†, Riccardo Cristofani ‡, Barbara Tedesco ‡, Marta Chierichetti †, Veronica Ferrari †, Elena Casarotto †, Marta Cozza †, Valeria Crippa †, Paola Rusmini †, Mariarita Galbiati †, Angelo Poletti †‡ and Elio Messi †

† Dipartimento di Scienze Farmacologiche e Biomoleculari (DISFeB), Centro di Eccellenza sulle Malattie Neurodegenerative, Università degli Studi di Milano, Milan, Italy, ‡ Unit of Medical Genetics and Neurogenetics, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

Breast cancer (BC) is a serious and widespread disease for which different treatments have been developed. In addition to the classic therapies, the treatment with retinoic acid (RA) is still being clinically investigated. RA reduces cancer cells proliferation and migration, but its molecular mechanism of action is not clear. In tumor development, autophagy promotes cancer cell survival and prevents apoptosis. Small heat shock protein B8 (HSPB8) acts together with its co-chaperone BCL-2 associated athanogene 3 (BAG3) stimulating BC proliferation and migration. We analyzed whether direct correlations exist between RA and HSPB8 or BAG3 and how this may play a role in BC. We measured HSPB8 and BAG3 gene expression in MCF-7 BC cells and we analyzed the potential correlation between the antiproliferative and antimigratory effect of RA with the expression level of HSPB8. We found that in MCF-7 cells RA reduces both HSPB8 and BAG3 gene expression and it alters the mitotic spindle organization. Notably, the effects of RA on HSPB8 levels are exerted both at transcriptional and translational levels acting also on HSPB8 mRNA levels. RA effects are possibly mediated by miR-574-5p that targets the HSPB8 transcript. Our results suggest that therapeutic doses of RA can efficiently counteract the adverse effects of HSPB8 in BC progression.

Keywords: retinoic acid, HSPB8, breast cancer, miRNAs, proliferation

INTRODUCTION

Breast cancer (BC) is both the most frequent cancer and the main cause of cancer-related death among women (1). A majority (~70%) of breast tumors express estrogen receptor (ER), and a significant fraction (~90%) of these ER-positive (ER+) breast tumors is also androgen receptor-positive (AR+) (2). It is now clear that ER+ BC should undergo specific anti-hormonal therapy (3) but, unfortunately, ~30-50% of initially responsive patients develop resistance to therapies (2), leading to the appearance of more aggressive tumor forms (2, 4).

Retinoids are vitamin A metabolites which act as differentiating agents, cell cycle progression inhibitors, and apoptosis inducers leading to growth arrest in different human cancer cell lines (5). A specific retinoid, all-trans retinoic acid (RA) is a standard therapy for promyelocytic leukemia, but
its use in solid cancer is still controversial (6). Unfortunately, few clinical investigations related to RA anticancer activity are available (7). Retinoids act through two subfamilies of nuclear retinoid receptors (RARs and RXRs) that belong to the family of steroid/thyroid hormone receptors. To date, six different genes encoding for nuclear RAR/RXRs have been identified. RAR/RXRs are ligand-activated transcription factor (TF) able to bind RA responsive elements (RAREs) located in the promoter of responsive genes (7). The interplay between RAR and ER was reported. Indeed, both receptors can bind the same DNA responsive elements and in ER+-MCF-7 cells, they act antagonistically to regulate human BC-associated genes (8).

Interestingly, also microRNAs (miRNAs) like miR-210, miR-23a/24-2, miR-17/92, miR-424/450b are antagonistically regulated by both estrogen and RA in MCF-7 cells (9). Noteworthily, RA treatment reduces the proliferation of ER+-MCF-7 but not of MDA-MB-231 cells, which are ER−; at the same time RA upregulates the expression of the pro-oncogenic miR-21 which reduces cellular motility, despite its ability to counteract RA antiproliferative activity (10). A study carried out on the ER SKBR3 cells showed that RA treatment modulates the expression of a considerably high number of miRNAs (11).

Chemoresistance of BC cells has been recently correlated with autophagy impairment mediated by miR-27a expression (12). Autophagy is one of the intracellular degradative systems responsible for the clearance of damaged proteins and organelles (13) and it is apparently involved in the generation of drug-resistant BC cells (14). In cancer cells, autophagy initially has a suppressive activity, but subsequently it can increase tumor cell survival by enhancing stress tolerability, perturbing cell function and reducing apoptotic cell death. Chaperone-assisted selective autophagy (CASA) is a peculiar form of autophagy, that exerts protective mechanisms against human diseases (15). A crucial player in CASA is the small Heat Shock Protein B8 (HSPB8), which acts as autophagy flux enhancer (16), together with its co-chaperone BCL2-associated athanogene 3 (BAG3), the Heat Shock Cognate 70 Protein (HSC70) and the E3-ubiquitin protein ligase CHIP (15, 17, 18). This CASA complex recognizes aberrant proteins and drives them to autophagosomes for their clearance (17–19). HSPB8 is a limiting component of the CASA complex (20), and its expression is associated with increased proliferation and migration of MCF-7 cells (21). Thus, HSPB8 plays a relevant role in the modulation of MCF-7 cell aggressiveness, and this action correlates with estrogen activity (21). While it is well-known that the retinoid system acts as a biological antagonist of the estrogenic system, among all the data collected about the effects of RA in BC none has been focused on its possible modulation of HSPB8 expression (16). The aim of this work was to analyze the direct effect of RA on HSPB8 expression in MCF-7 cells and its possible role in preventing the adverse effects of HSPB8 in BC. We found that RA reduces HSPB8 transcription and translation by acting on its promoter and on its mRNA stability, respectively, and this results in a disruption of the correct structure of the mitotic spindle. Our data also showed that the HSPB8 mRNA could be targeted in its open reading frame (ORF) by miRNAs that can regulate HSPB8 mRNA stability, one of which is miR-574-5P. Thus, RA may be viewed as a potent physiological antagonist of HSPB8 adverse activities in BC.

**MATERIALS AND METHODS**

**Chemicals**

17β-estradiol (#E1024), all-trans retinoic acid (RA; #R2625) and ICI 182.780 (#I4409) were obtained from Sigma-Aldrich (St. Louis, MO, USA).

**Cell Culture and Treatments**

MCF-7 and MDA-MB-213 cells were originally obtained from the American Type Culture Collection (Rockville, MD) and are routinely used in our laboratory between passages 8 and 12 (21) (5% CO2, 37° C, humidity > 90%). Short-tandem repeat (STR) profile has been performed by Eurofins Genomics Europe (Ebersberg, Germany). Genetic characteristics were determined by PCR-single-locus-technology. 16 independent PCR-systems (D8S1179, D21S11, D7S820, CSF1PO, D3S1358, TH01, D13S317, D165539, D251338, AMEL, D5S818, FGA, D19S433, vWA, TPOX and D18S51) were investigated (Table 1). Before any experimental procedure, medium was replaced overnight with RPMI 1640 without fetal bovine serum (FBS) and without phenol red to synchronize cell growth. In all experiments, 17β-estradiol was used at the dose of 10nM and RA at doses ranging from 0.01μM to 1μM accordingly to literature (21–23). Plasmid transfection was performed on the third day of RA treatment. The immortalized motoneuronal NSC-34 cells were obtained from Niel Cashman and are routinely used in our laboratory between passages 10 and 20 (24, 25).

**Plasmids, miR-Inhibitor and Transfection**

pCMV-β-gal plasmid was obtained from Clontech Lab (Mountain View, CA, USA). hProm88-LUC plasmid contains the firefly luciferase cDNA under the control of a -3000/+523 human HSPB8 promoter region (18); pCI-hHSPB8-wild-type (wt) codes for the human HSPB8 protein (26). HSPB8-mut has been obtained in our laboratory by exchanging the Apal/Sall coding fragment with the mutated sequence obtained from Eurofins Genomics. pEGFP-G93A-SOD1 expresses the green fluorescent protein (GFP)-tagged mutant G93A SOD1 (17). pcDNA3.1 (Life Technologies, #V790-20) plasmid was used to normalize the amount of transfected plasmid DNA. All plasmids were transfected in MCF-7 and MDA-MB-213 cell lines as previously described (21). NSC-34 cells were transfected as previously described (25). The hsa-miR-574-5p miRCURY LNA miRNA Inhibitor (Qiagen) was used to inhibit miR-574-5p activity, and the miRCURY LNA miRNA Inhibitor Control (Qiagen) was used as a control. Both miRNAs were transfected at the final concentration of 50nM according to the manufacturers instructions.
TABLE 1 | Cell Line Authentication. The table shows the result of the cell line analysis.

| Sample Name | MCF-7 | MDA-MB-231 |
|-------------|-------|------------|
| D8S1179     | 10.14 | 13.13      |
| D21S111     | 30.30 | 30.33.2    |
| D7S820      | 8.9   | 8.8        |
| CSF1PO      | 10.10 | 12.13      |
| D9S1085     | 16.18 | 16.16      |
| TH01        | 6.6   | 7.93       |
| D13S317     | 11.11 | 13.13      |
| D16S539     | 11.12 | 12.12      |
| D2S1338     | 21.23 | 20.21      |
| D19S433     | 13.14 | 11.14      |
| vWA         | 14.15 | 15.15      |
| TPOX        | 9.12  | 8.9        |
| D18S51      | 14.14 | 11.16      |
| AMEL        | XX    | XX         |
| D5S818      | 11.12 | 12.13      |
| FGA         | 23.25 | 22.23      |
| Database Name | MCF-7 | MDA-MB-231 |

RT-qPCR Analysis
MCF-7 and MDA-MB-231 cells were seeded in 6-well plates at 300,000 cells/well and treated for 2 or 3 days with increasing doses of RA (0.01-1μM) and with 17β-estradiol (10nM). Then, cells were harvested in 300 μL TRI Reagent (Sigma-Aldrich; #T9424) and total RNA was isolated. 1μg total RNA was treated with DNase and reverse-transcribed into cDNA using the High-Capacity cDNA Archive Kit (Applied Biosystems, Life Technologies Corporation; #4368813). Primers were synthetized by Eurofins Genomics with the sequences reported in Table 2. Real-time PCR (qPCR) was performed as previously described (21). Data were transformed using the equation 2^(-ΔΔCt) to give N-fold changes in gene expression; all statistical analyses were performed with ΔCt values. Each sample was analyzed in triplicate (n=3); HSPB8 and BAG3 values were normalized to those of Ribosomal Protein Lateral Stalk Subunit P0 (RPLP0).

Western Blot Assay
MCF-7 and MDA-MB-231 cells were seeded in 6-well plates at 300,000 cells/well and treated for 2 or 3 days with increasing doses of RA (0.01-1μM) and with 17β-estradiol (10nM). Western blot (WB) assay was performed as previously described (21). NSC-34 cells were seeded in 12-well plates at 80,000 cells/well. 48h after transfection, cells were harvested and centrifuged for 5 min at 100 x g at 4°C; the cell pellets were then re-suspended in Phosphate-Buffered Saline (PBS) (Sigma-Aldrich) added with a protease inhibitor cocktail (Sigma-Aldrich) and homogenized using slight sonication to lyse cells and nuclei. Total protein concentration was determined using the bicinchoninic acid method (BCA assay; Euroclone, EMP014500). Equal amounts of proteins (15-20μg) were resolved by electrophoresis on a 10-15% SDS-polyacrylamide gel (SDS-PAGE). Proteins were transferred to 0.45 μm nitrocellulose membranes using a transfer apparatus (Mini Trans-Blot Cell; Bio-Rad Laboratories). The membranes were then processed as previously described (21). For HSPB8, Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH) and α-Tubulin detection, overnight incubation at 4°C was performed respectively with antibodies listed in Table 3. Membranes were then washed and incubated for 1 h at room temperature with secondary antibodies conjugated to peroxidase (Table 3). Immunoreactive bands were visualized using enhanced chemiluminescence detection kit reagents (Westar Antares; Cyanagen, XLS142). A ChemiDoc XRS System (Bio-Rad) was used for image acquisition.

Immunofluorescence Analysis
MCF-7 cells were plated on 13mm-diameter coverslips at 50,000 cells/well and treated with RA (1μM) for 2 or 3 days, then fixed in 4% paraformaldehyde, permeabilized in 0.5% Triton X-100 and treated with 5% FBS (GIBCO) in PBS. Subsequently, cells were incubated overnight at 4°C with the primary antibodies listed in Table 3. Incubation with secondary antibodies (Table 3) was performed for 1 h at room temperature. Nuclei were stained with Hoechst 33342 (Thermo Fisher). Finally, the coverslips were mounted with Mowiol 40-88 (Sigma-Aldrich). Images were collected by UIC-Metavue 6.2.2 (UIC-Crisel Instr. Rome) imaging system on an Axiavert Zeiss 200 microscope, utilising a 0× magnification (NA 0.8) objective.

Cell Growth Studies
To study the effect of RA and 17β-estradiol on MCF-7, cells were seeded in 24-well plates at 40,000 cells/well and treated up to 6 days with increasing doses of RA (0.01-1μM) and with 17β-estradiol (10nM). Western blot (WB) assay was performed as previously described (21). NSC-34 cells were seeded in 12-well plates at 80,000 cells/well. 48h after transfection, cells were harvested and centrifuged for 5 min at 100 x g at 4°C; the cell pellets were then re-suspended in Phosphate-Buffered Saline (PBS) (Sigma-Aldrich) added with a protease inhibitor cocktail (Sigma-Aldrich) and homogenized using slight sonication to lyse cells and nuclei. Total protein concentration was determined using the bicinchoninic acid method (BCA assay; Euroclone, EMP014500). Equal amounts of proteins (15-20μg) were resolved by electrophoresis on a10-15% SDS-polyacrylamide gel (SDS-PAGE). Proteins were transferred to 0.45 μm nitrocellulose membranes using a transfer apparatus (Mini Trans-Blot Cell; Bio-Rad Laboratories). The membranes were then processed as previously described (21). For HSPB8, Glyceraldehyde 3-Phosphate Dehydrogenase (GAPDH) and α-Tubulin detection, overnight incubation at 4°C was performed respectively with antibodies listed in Table 3. Membranes were then washed and incubated for 1 h at room temperature with secondary antibodies conjugated to peroxidase (Table 3). Immunoreactive bands were visualized using enhanced chemiluminescence detection kit reagents (Westar Antares; Cyanagen, XLS142). A ChemiDoc XRS System (Bio-Rad) was used for image acquisition.

Table 3 | Antibody list.

| Antibody | Species | Dilution | Application | Company (Catalog #) |
|----------|---------|----------|-------------|---------------------|
| HSPB8    | rabbit  | 1:2000   | WB          | kindly provided by Jacques Landry, Quebec, Canada |
| BAG3     | rabbit  | 1:10,000 | WB          | Abcam; #ab47124 |
| α-Tubulin| mouse   | 1:1,000  | WB          | Sigma-Aldrich; #T6199 |
| GFP      | mouse   | 1:1000   | WB/FPA      | Immunological Sciences; #MAB94345 |
| Anti-rabbit | goat  | 1:10,000 | WB (HSPB8) | Santa Cruz Biotech; #E2908 |
| Anti-mouse | donorkey | 1:500 | IF (red) | Rockland; #611-700-127 |
| Anti-rabbit | donorkey | 1:500 | IF (green) | Rockland; #710-702-124 |
| Anti-mouse | goat   | 1:200    | IF         | Thermo Fisher; #A11070 |

TABLE 2 | Primer List.

| Gene   | Sequence (5’-3’) |
|--------|-----------------|
| HSPB8  | AGAGGAAGTTGGATGTTGAAGACC CTGCGAGAAGCTGTTTC TGGTGGAGGCAAACACCTAAG AGACAGTGCAACACCACAGC | |
| BAG3   | GGGTGGAGGCAAACACCTAAG AGACAGTGCAACACCACAGC GTGGCGGAGGCAAGAATGTOGG TGCACATCATGTTGTCTTG | |
| RPLP0  | forward reverse | |

Frontiers in Oncology | www.frontiersin.org 3 Month 2021 | Volume 11 | Article 652085
days with RA (1 uM) and 17β-estradiol (10nM); cell growth/ viability was measured by MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] assay. Briefly, culture medium was replaced with fresh medium containing MTT (1.5 mg/ml) and the multiwells were incubated at 37°C for 1 h, then the medium was removed and 2-propanol (500µl) was added to solubilize the crystals. The absorbance was read at 550 nm with an EnSpire 2300 Multimode Plate Reader (Perkin Elmer, Italy) (21).

miRNA RT-qPCR Analysis

10ng of total RNA were reverse-transcribed and amplified using the miRCURY LNA miRNA PCR Starter Kit (Qiagen, Ref 339320). The kit includes a spike-in control primer set (UniSp6), UniSP6 RNA Spike-in-template, one candidate endogenous control primer set (miR-103a-3p) and two validated primer sets, which in our case were miR-297 (Qiagen YP00206079) and miR-574-5p (Qiagen YP02116206). As additional control micro-RNAs (miRNAs), we chose miR-25-3p (Qiagen YP00204361) and miR-331-3p (Qiagen YP0020646) because both are used as markers in BC analysis (27, 28) and their expression is not modified by RA treatment in the BC cell line SKBR3 (11). Real-time PCR was performed with miRCURY LNA SYBR Green Master Mix (Qiagen) in 10µl total volume using the CFX 96 Real Time System (Bio-Rad). The expression of target miRNAs miR-297 and miR-574-5p was normalized against miR-25-3p and miR-103a-3p, miR-331-3p and UniSp6 using the 2-ΔΔCT method. To validate the real-time system used for miRNA analysis, we measured the levels of UniSp6RNA, a control RNA provided with the Starter Kit, that was added before the reverse transcription in equal amount to all samples (see Supplementary material).

Transcriptional Activity

Transcriptional activity was measured using the LucLite Kit from Perkin Elmer (Waltham, MA, USA). MCF-7 cells treated with RA (1uM) and 17β-estradiol (10nM) were plated in 24-well plates at a density of 100,000 cells/well and transfected with 0.4µg pCMV-β-gal plasmid and with 0.6µg hPromB8-LUC plasmid. Each sample was analyzed in sextuplicate. All plasmids were transfected as described above. The inducible firefly luciferase activities controlled by the HSPB8 promoter have been normalized using the constitutive β-galactosidase activities produced under the control of the Citomegalovirus (CMV) promoter (by co-transfecting pCMV-β-gal). The luminescence was evaluated using Wallac 1450 MicroBeta TriLux (Perkin Elmer, Waltham, MA, USA). β-galactosidase activity (coded by pCMVβ) was then assayed in the same samples. For β-galactosidase 50µl of each sample were added to 750µl Assay Buffer in presence of 4mg/ml β-galactosidase substrate o-nitrophenyl-β-D-galactopyranoside (ONPG, Sigma) and incubated at 37°C until yellow color appeared. Then, 500µl Na2CO3 (1M) were added, 200µL of the final solution were transferred to 96-well plates and 420nm absorbance was quantified using EnSpire 2300 Multimode Plate Reader (Perkin Elmer, Italia).

Filter Retardation Assay

NSC-34 cells were plated at 80,000 cells/well in 12-well plates, transfected and collected 48h after transfection in PBS added with protease inhibitor. Cells were homogenized using slight sonication to lyse cells and nuclei as previously described (29). Filter retardation assay (FRA) was performed using a Bio-Dot SF Microfiltration Apparatus (Bio-Rad). 6µg of the total protein extracts were filtered through 0.22µm cellulose acetate membranes (Whatman, 100404180). The membranes were probed as described for WB. A ChemiDoc XRS System (Bio-Rad) was used for image acquisition. The optical density of samples assayed with WB or FRA was detected and analyzed using the Image Lab software (Bio-Rad). Statistical analyses were performed using relative optical densities, defined as the ratio between the optical densities of each independent biological sample (n = 3) and the mean optical density of control samples.

Migration Assay

Briefly, cell migration assay was performed using a 48-well Boyden chamber (NeuroProbe, Inc., Gaithersburg, MD, USA) containing 8µm polycarbonate filters (Nucleopore, Concorezzo, Milan, Italy). Filters were coated on one side with 50µg/ml laminin rinsed once with PBS, and then placed in contact with the lower chamber containing RPMI 1640 medium. MCF-7 cells, overexpressing mutated HSPB8 for 3 days and treated with 1µM RA up to 6 days, were collected, added in aliquots (75,000 cells/50µl) to the top of each chamber and allowed to migrate through coated filters for 4h. At the end of the incubation, the migrated cells attached on the lower membrane surfaces were fixed, stained with Diffquik (Biomap, Italy) and counted in standard optical microscopy (21).

Statistical Analysis

Statistical analysis was performed by one-way ANOVA followed by Bonferroni multiple comparison tests. *p<0.05 was considered statistically significant. Computations were performed with the PRISM (ver. 6.0 h) software (GraphPad Software, LaJolla, CA, USA).

RESULTS

Effect of RA on HSPB8 and BAG3 Gene Expression

We initially evaluated whether RA may modulate HSPB8 expression in MCF-7 cells. For this purpose, we treated MCF-7 with increasing doses of RA for 2 or 3 days, accordingly to the literature (23). The analysis of HSPB8 gene expression, performed using RT-qPCR on MCF-7 cells, is reported in Figure 1A. The data clearly show that both 2 and 3 days of 1µM RA treatment resulted in a significant reduction of HSPB8 mRNA levels, while lower doses were not able to modify HPSB8 expression at both times considered. A similar result was observed for HSPB8 protein by western blot (WB) analysis (Figure 1B): in fact, no significant modulation of HSPB8 protein levels was observed after 2 and 3 days of treatment
with the lowest doses of RA, while 1μM RA treatment reduced HSPB8 levels. Similarly, also BAG3 mRNA and protein levels were reduced by RA (Figures 1C, D). Moreover, we performed Immunofluorescence (IF) analysis to evaluate HSPB8, BAG3 and tubulin intracellular localization (Figures 1E, F). HSPB8 and BAG3 intracellular distribution in untreated cells was in line with our previous observations (21). Interestingly, in MCF-7 cells treated with 1μM RA the HSPB8 and BAG3 IF reactivities were significantly reduced at both times considered (Figures 1E, F), while they were easily detectable in untreated cells. No changes in tubulin levels and distribution were observed after 2 days of RA treatment, but several dividing cells displayed a different organization of their normal mitotic asset after 3 days of RA treatment. As described by Fuchs and colleagues (30), HSPB8 has a very peculiar localization at metaphase, since it surrounds the complex microtubule spindle network and concentrates adjacent to, but not co-localizing with the chromosomal DNA packed at the metaphase plate. In Figure 1I, we showed that HSPB8 reduction induced by RA treatment was associated with the alteration of the mitotic spindle, that appeared highly disorganized, impairing the correct chromosomes alignment. Therefore, our data suggest that the effects of HSPB8 on

**FIGURE 1** | Effect of RA treatment in MCF-7 cells. HSPB8 (A, B) and BAG3 (C, D) mRNA and protein levels measured by RT-qPCR analysis and western blot analysis in MCF-7 cells treated for 2 and 3 days with different doses of RA. (E) Immunofluorescence analysis of HSPB8 (red) and tubulin (green) in MCF-7 cells treated for 2 and 3 days with 1μM RA, nuclei were stained with Hoechst (scale bar = 20μm). (F) Immunofluorescence analysis of BAG3 (red) and tubulin (green) in MCF-7 cells treated for 2 and 3 days with 1μM RA (scale bar = 20μm). (G, H) Fluorescent intensity quantification of HSPB8 and BAG3, nuclei were stained with Hoechst. (I) Higher magnification of the mitotic spindle (scale bar = 5μm). *p<0.05, **p<0.01 and ***p<0.005 in all charts. *p<0.05; **p<0.01; ***p<0.005 vs control. Graph bars represent the mean of three independent experiments.
microtubules could be more relevant during the mitotic phase than during interphase, since the alteration on the tubulin network induced by HSPB8 downregulation was present only on the microtubules forming the mitotic spindle.

**Dual Activity of RA on HSPB8 Transcript Levels**

The reduction of HSPB8 gene expression operated by RA suggests that there may be a direct action on the promoter region of the human HSPB8 gene. To evaluate this hypothesis, we took advantage of the reporter plasmid hPromB8-LUC, in which the cDNA coding for luciferase is placed under the control of the human HSPB8 promoter (18). We transfected MCF-7 cells with the plasmid and analysed RA effect on luciferase expression, both in basal condition and in the presence of 10nM 17β-estradiol, used as positive control (21) (Figure 2A). At 2 days of treatment, we found that RA had no effect in basal condition, whilst it significantly reduced 17β-estradiol-induced luciferase activity. Consistently, we confirmed that, in our experimental condition, RA treatment was able to reduce cell proliferation induced by 17β-estradiol treatment, as already published by Salvatori and colleagues (23) (Figure S2).

To investigate the possible correlation between RA and 17β-estradiol in the modulation of HSPB8 expression, we inhibited ER activation in MCF-7 with the ER antagonist ICI 182.780 and analysed HSPB8 expression by RT-qPCR (Figure 2B) and WB (Figure 2C). The data clearly showed that both ICI 182.780 and RA treatments resulted in a significant reduction of HSPB8 mRNA levels; moreover ICI 182.780 and RA co-treatment showed a synergic effect (Figure 2B). A similar result was observed for HSPB8 protein levels (Figure 2C), suggesting that ER is necessary to maintain HSPB8 expression, but RA effects might be exerted independently from the ER activity on HSPB8 promoter (21).

Then, we assessed the possibility that RA effects on HSPB8 expression levels were independent from HSPB8 promoter regulation. For this purpose, we transfected MCF-7 cells with a plasmid in which HSPB8 expression is regulated by the Citomegalovirus (CMV) promoter. We found that, also in this case, RA reduced both mRNA (Figure 2D) and protein levels (Figure 2E) of overexpressed HSPB8 in MCF-7 cells, at every time considered. Moreover, we confirmed that this effect was specific for HSPB8, since no modulation was observed on the β-galactosidase enzyme expressed under the control of CMV promoter (Figure S3).

Therefore, the RA-mediated reduction of HSPB8 levels might depend on a specific RA-regulated factor, that might act at mRNA level, like, for example a micro-RNAs (miRNAs).

---

**FIGURE 2** | Promoter independent modulation of HSPB8 is induced by RA in MCF-7 cells. (A) Transcriptional activity assay of MCF-7 cells treated with 1μM RA and/or 10nM 17β-estradiol transfected with hPromB8-LUC and pCMV-β-gal. Luciferase activity is expressed as luminescence counts per second (LCPS) normalized on β-galactosidase (β-gal) expression. HSPB8 mRNA (B) and protein levels (C) measured by RT-qPCR analysis and western blot analysis in MCF-7 cells treated for 2 days with 1μM RA and/or 100nM ICI 182.780. (D) HSPB8 mRNA levels measured by RT-qPCR analysis in MCF-7 cells. (E) HSPB8 protein levels measured by western blot analysis in MCF-7 cells. For D, E untreated cells (C), mock-transfected cells (M) or cells treated up to 6 days with 1μM RA and transfected at day 3 with the plasmid overexpressing wild-type HSPB8. Analyses were performed at 1, 2 and 3 days after transfection.
miRNA Analysis in MCF-7 and MDA-MB-231 Cells and Effects of RA Treatment

Our data suggest that endogenous and overexpressed HSPB8 could be the target of one or more miRNAs, possibly modulated by RA in MCF-7 cells. It is expected that a putative miRNA should be capable of binding in the HSPB8-mRNA open reading frame (ORF); in fact, the transcript derived from pCI-hHSPB8 lacks the 5'-untranslated region (5'-UTR) and the 3'UTR of endogenous HSPB8 mRNA. By scanning HSPB8 cDNA in silico (http://www.mirbase.org) for sequences complementary to known miRNAs, we identified some putative miRNAs that target the ORF region of HSPB8 mRNA (Table 4). Of these, only miR-297 and miR-574-5p were confirmed by a subsequent analysis (http://ophid.utoronto.ca/mirDIP). Both are able to bind HSPB8 mRNA region comprised between 781bp and 799bp (Figure 3A).

We thus measured the levels of the two selected miRNAs in MCF-7. miR-297 levels did not show any significant variation upon 1μM RA treatment for 4 days (Figure 3B). Otherwise, the same treatment caused a significant reduction of miR-574-5p levels (Figure 3C). In order to exclude a possible RA effect on control miRNA levels, we used 3 different control miRNAs (miR-25-3p, miR-331-3p, and miR-103a-3p) to normalize the results. Notably, the reduction of miR-574-5p levels in MCF-7 cells was observed in all the analyzed conditions. Moreover, at 6h, 24h, and 48h of RA treatment we did not observe miR-574-5p reduction (Figure 3D).

Then, we treated MCF-7 cells with hsa-miR-574-5p miRCURY LNA miRNA inhibitor, but unfortunately we did not observe a modulation of HSPB8 protein levels after its overexpression (Figure 3E). Despite this, we assayed the levels of miR-297 and miR-574-5p also in the ER-MDA-MB-231 cell line, that express low levels of HSPB8. miRNA levels in the two cell lines have been compared using UnSp6RNA as external reference to normalize samples. Interestingly, miR-574-5p levels were significantly higher in MDA-MB-231 cells compared to MCF-7 cells (Figure 3F). No differences were observed in the case of miR-297 levels (Figure 3G).

This evidence led us to test the effect of RA on overexpressed HSPB8 also in MDA-MB-231 cells. Data showed that RA treatment did not affect HSPB8 mRNA (Figure 3H) and protein levels (Figure 3I). Consistently, we did not observe changes in miR-574-5p in MDA-MB-231 cells after exposure to RA (Figure 3J). miR-297 levels did not change in the same experimental conditions (Figure S4).

Effect of RA on MCF-7 Cell Proliferation and Migration in Presence of HSPB8 Variant Overexpression

To deeply assess whether miR-574-5p mediates the RA effect on HSPB8 levels, we edited miR-574-5p target sequence from HPSB8-coding plasmid to avoid miRNA interaction. We designed the mutation in order to minimize changes in protein structure that might alter its functions and/or turnover. We preferentially removed guanine and cytosine to weaken miRNA/miRNA interaction in order to reduce the highest hydrogen bonds number changing the lowest base pair (Figures 4A, B). As shown in Figure 4C, the HSPB8 mutated variant has three Val-to-Leu conservative replacements in positions 98, 100 and 102. Since miR-574-5p target region is localized in the first part of the alpha-crystalline domain, that is a well-structured domain essential for HSPB8 activity, we initially ruled out that the introduced mutations did not affect the expression level/stability and the activity of mutant HSPB8 (Figure S5). Then, we overexpressed HSPB8 mutated variant in both MCF-7 and MDA-MB-231 cells, and we analyzed the effect of RA treatment on the overall HSPB8 mRNA and protein levels. Surprisingly, RA treatment correlated with a further increase of HSPB8 mRNA levels at 1 and 2 days after transfection (Figure 4D), while HSPB8 protein levels were enhanced only at day 1 after transfection in MCF-7 cells (Figure 4E). Interestingly, this unexpected stimulatory effect of RA was not observed in MDA-MB-231 cells (Figures 4F, G). Since RA treatment in MCF-7 cells overexpressing HSPB8 variant did not cause a reduction of total HSPB8 levels, that remained elevated up to 3 days after transfection, it was possible to assess whether RA treatment was able to reduce MCF-7 cell proliferation even in presence of high HSPB8 protein levels. The data in Figure 4H showed that the presence of overexpressed HSPB8 variant did not change the proliferative capacity of MCF-7 cells and that RA maintained its antiproliferative activity even under these conditions. Finally, we also assessed RA antiproliferative capacity of MCF-7 cells in the presence of the HSPB8 variant. We found that RA was able to reduce the migratory capacity of MCF-7 cells from 4 to 6 days of treatment. Interestingly, this effect was completely counteracted by HSPB8 variant starting from the fifth day of treatment and after 2 days post transfection (Figure 4I).

### Table 4 | miRNAs targeting HSPB8 ORF.

| Accession ID | Query start | Query end | Subject start | Subject end | Strand |
|--------------|-------------|-----------|---------------|-------------|--------|
| hsa-miR-6727-5p | 37 | 55 | 1 | 19 | - |
| hsa-miR-6882-3p | 75 | 93 | 6 | 24 | + |
| hsa-miR-370-3p | 436 | 454 | 2 | 20 | + |
| hsa-miR-297 | 290 | 308 | 1 | 19 | + |
| hsa-miR-6075 | 35 | 53 | 2 | 20 | - |
| hsa-miR-6509-5p | 22 | 40 | 2 | 20 | + |
| hsa-miR-6509-3p | 22 | 40 | 1 | 19 | + |
| hsa-miR-6842-3p | 158 | 176 | 2 | 20 | + |
| hsa-miR-574-5p | 292 | 306 | 8 | 22 | + |

In grey are highlighted the miRNA confirmed by the analysis done with mirDIP. The table shows the result of in silico analysis of HSPB8 ORF with miRbase database.
The study here described is based on our previous demonstration that HSPB8 modulates the proliferation and migration of ER+ BC MCF-7 cells. These cells express HSPB8 protein and mRNA at higher levels compared to ER- BC MDA-MB-231 cells (21). Moreover, estrogen-induced HSPB8 expression is absent in MDA-MB-231 cells (21). This suggests that HSPB8 translation is differentially modulated by transcriptional regulatory mechanisms in the two cell types. It is also known that these cells are differently sensitive to RA treatment, that selectively affects the expression of many genes (31) and miRNAs (11).

Therefore, we decided to analyze the direct effect of RA on endogenous HSPB8 gene expression in MCF-7 cells and on overexpressed HSPB8 in both MCF-7 and MDA-MB-231 cells. We clearly observed that RA reduces HSPB8 and BAG3 gene expression in MCF-7 cells. Since HSPB8 has been shown to induce MCF-7 cell proliferation (21), we postulated that the well-known antiproliferative action exerted by RA on BC cells may also take place through the downregulation of HSPB8 and its co-chaperone BAG3. A possible mechanism of action of RA on
FIGURE 4 | Effects of RA treatment in MCF-7 cells overexpressing miR-574-5p mutated HSPB8 variant. (A) Alignment of the ORF region (between 780 and 800bp) of wild-type HSPB8 DNA with mutated HSPB8 DNA. (B) Alignment of miR-574-5p RNAs with mutated HSPB8 mRNA ORF region (between 780 and 800 basis), capital letters indicate the miRNA seed sequence. (C) Alignment of wild-type HSPB8 protein sequences with the mutated one, bracket indicate the aminoacids coded by the mRNA region between 780 and 800 basis. (D) HSPB8 mRNA measured by RT-qPCR analysis in MCF-7 cells. (E) HSPB8 variant protein levels measured by western blot analysis in MCF-7 cells. (F) HSPB8 mRNA measured by RT-qPCR analysis in MDA-MB-231 cells. (G) HSPB8 variant protein levels measured by western blot analysis in MDA-MB-231 cells. For (D-G) untreated cells (C), mock-transfected cells (M) or cells treated up to 6 days with 1μM RA and transfected at day 3 with the plasmid overexpressing miR-574-5p mutated HSPB8 variant. Analyses were performed at 1, 2 and 3 days after transfection. (H) Proliferation of MCF-7 cells overexpressing the miR-574-5p mutated HSPB8 variant for 3 days and treated with 1μM RA up to 6 days, values are expressed as percentage on day 3 of RA treatment. (I) Migration of MCF-7 cells overexpressing the miR-574-5p mutated HSPB8 variant for 3 days and treated with 1μM RA up to 6 days, values are expressed as number of migrated cells (% vs untransfected control). *p<0.05; **p<0.01; ***p<0.005 in all charts. Graph bars represent the mean of three independent experiments.
MCF-7 proliferation is the mitotic spindle disorganization and incorrect placement of chromosomes in dividing HSPB8-depleted cells. In fact, the HSPB8-BAG3 complex regulates actin dynamics during mitosis by influencing spindle orientation, a process required for chromosome alignment at the metaphase plate and chromosome segregation (30), and already proven to be a target for BC therapy (32). HSPB8 or BAG3 silencing resulted in a disorganization of actin-rich retraction fibers and altered spindle orientation, so the HSPB8-BAG3 complex mediates the protein quality control mechanism during mitotic processes activated in proliferating cells (30).

We found that RA inhibits HSPB8 expression acting on its promoter, when its expression is enhanced by 17β-estradiol, known to be a powerful positive regulator of HSPB8 expression (21, 22); these data agree with other reports demonstrating the antagonism between RA receptors and ERs on their DNA responsive elements (8). Accordingly to other Authors (23), we also report that the stimulatory action of 17β-estradiol exerted on MCF-7 cell proliferation is antagonized by RA treatment, and that RA antiproliferative effect is exerted only at a late stage after treatment. We also determined whether RA effects on MCF-7 cells occurs even in the presence of HSPB8 overexpression. Surprisingly, high HSPB8 protein levels achieved upon HSPB8 overexpression, were reduced by RA treatment. Interestingly, this effect occurred when HSPB8 expression was driven by the exogenous CMV promoter in the encoding plasmid lacking the human HSPB8 promoter. We excluded that RA acts on the CMV promoter using the same promoter to drive the expression of the reporter cDNA expressing β-galactosidase. In addition, MDA-MB-231 cells transfected with the same HSPB8-coding plasmid did not show any decrease of HSPB8 protein levels upon RA treatment. Thus, RA must post-transcriptionally act on HSPB8 mRNA through a RA-induced factor in MCF-7 cells (and not in MDA-MB-231 cells), such as a miRNA, capable of decreasing HSPB8 mRNA levels and preventing its translation into the protein. Some miRNAs are capable of binding to HSPB8 mRNA (33, 34), but those of our interest should be also regulated by RA. MiRNAs targeting the 3′-UTR or 5′-UTR were excluded since both regions are absent in our HSPB8 plasmid; therefore the putative miRNA must directly target the ORF region of HSPB8 mRNA. In silico analysis showed some miRNAs interacting with the ORF region of HSPB8 mRNA and among these our attention focused on miR-297 and 574-5p, both able to bind in the same tract between 780bp and 800bp. So far, miR-297 has never been reported in any BC study, even if it was identified as tumor suppressor in prostate cancer (35), in colorectal cancer (36) and glioblastoma (37), while in pulmonary adenocarcinoma it has an oncogenic effect (38). Conversely, miR-574-5p is highly expressed in the triple negative BC SKBR3 cell line (11) where it acts as tumor suppressor (39, 40). We found that miR-297 and miR-574-5p are expressed in MCF-7 and MDA-MB-231 cells, but only miR-574-5p is downregulated by RA specifically in MCF-7 cells in which it correlates with the reduction of HSPB8 expression. The opposite has been observed in MDA-MB-231 cells, that express higher levels of miR-574-5p possibly compensating for the lower levels of HSPB8 mRNA (21). Thanks to a HSPB8 cDNA mutated in the putative target sequence of miR-574-5p, we confirmed that this HSPB8 ORF specific region is involved in RA-mediated downregulation of HSPB8, since RA treatment is not able to affect mutated HSPB8 mRNA and protein levels in MCF-7 cells. We also confirmed that RA reduces BC cells migration (41) and counteracts the pro-migratory activity of HSPB8 in MCF-7 cells (21). We characterized the possible physiological antagonism between

![Schematic representation of the RA effects on MCF-7 cells unveiled in this study.](Image 5)
miR-574-5p and the HSPB8 mutated variant on RA antimigratory effect, further proving that high HSPB8 levels are counteracted by RA, making cells refractory to its action on migration.

The data here reported suggest that in MCF-7 cells RA reduces HSPB8 gene expression modulating the proliferative and migratory activity of this cell line. RA inhibitory action on MCF-7 proliferation and migration is also exerted in the presence of high levels of HSPB8. We identify the miR-574-5p as a modulator of HSPB8 expression by its binding to HSPB8 ORF.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

Conceptualization, MP, RC, AP, and EM. Methodology, MG, VC, and PR. Validation BT and VF Investigation, MCh and MCo. Writing—Original Draft Preparation, EM, MP, RC, and AP. Writing—Review & Editing, MG, VC, PR, BT, VF, MCh, MCo, and MG. Supervision, AP. All authors contributed to the article and approved the submitted version.

FUNDING

This research was funded by: Fondazione Telethon, Italy (n. GGP14039 to AP, GGP19128 to AP); Kennedy’s disease association (grant to RC); Fondazione Cariplo, Italy (n. 2014-0686 to AP; n. 2017_0747 to VC); Fondazione AriSLA, Italy (n. ALS_HSPB8 to AP; ALS_Granulopathy to AP; MLOpathy to AP; Target-RAN to AP); Association Francaise contre les Myopathies, France (AFM Teledonn n. 16406 to AP); Università degli Studi di Milano e piano di sviluppo UNIMI—linea B (to VC and PR); Bando Stradordinario per Progetti Interdipartimentali (Bando SEED 2019: #TDP-43-iPSC to VC) Italian Ministry of University and Research (MIUR), PRIN—Progetti di ricerca di interesse nazionale (n. 2015LFPNMM to AP; n. 2017F2AA25 to AP); Fondo per il Finanziamento delle Attività Base di Ricerca (FFABR) (MIUR, to MG, EM, and to PR); Agenzia Italiana del Farmaco (AIFA) (Co_ALS to AP); Fondazione Regionale per la Ricerca Biomedica (FRBB) (Regione Lombardia, TRANS_ALS, project nr. 2015-0023, to AP). EU Joint Programme—Neurodegenerative Disease Research (JPND) project. The project is supported through the following funding organizations under the aegis of JPND—www.jpnd.eu. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement N° 643417 [Grant ID: 01ED1601A, CureALS] (to AP); Italian Ministry of University and Research [Progetto Dipartimenti di Eccellenza].

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.652085/full#supplementary-material
